399 related articles for article (PubMed ID: 26166130)
1. Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.
Yuan JQ; Mao C; Wong SY; Yang ZY; Fu XH; Dai XY; Tang JL
Medicine (Baltimore); 2015 Jul; 94(27):e974. PubMed ID: 26166130
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis.
Wang X; Wang X; Li S; Meng Z; Liu T; Zhang X
PLoS One; 2014; 9(9):e107593. PubMed ID: 25216271
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
5. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
[TBL] [Abstract][Full Text] [Related]
7. Finasteride for benign prostatic hyperplasia.
Tacklind J; Fink HA; Macdonald R; Rutks I; Wilt TJ
Cochrane Database Syst Rev; 2010 Oct; 2010(10):CD006015. PubMed ID: 20927745
[TBL] [Abstract][Full Text] [Related]
8. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
Zhang J; Li X; Yang B; Wu C; Fan Y; Li H
World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD010060. PubMed ID: 30480763
[TBL] [Abstract][Full Text] [Related]
10. To evaluate the efficacy and safety of different kinds of PDE5-Is with tamsulosin as a medical therapy for LUTS secondary to benign prostatic hyperplasia: A protocol for systematic review and meta analysis.
Ma C; Zhang J; Cai Z; Li H
Medicine (Baltimore); 2020 Jan; 99(3):e18712. PubMed ID: 32011446
[TBL] [Abstract][Full Text] [Related]
11. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Hwang EC; Gandhi S; Jung JH; Imamura M; Kim MH; Pang R; Dahm P
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007360. PubMed ID: 30306544
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
Yan H; Zong H; Cui Y; Li N; Zhang Y
J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
[TBL] [Abstract][Full Text] [Related]
13. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
14. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Garimella PS; Fink HA; Macdonald R; Wilt TJ
Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.
Wang XH; Wang X; Shi MJ; Li S; Liu T; Zhang XH
Asian J Androl; 2015; 17(6):1022-32. PubMed ID: 25994648
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis.
Yoosuf BT; Panda AK; Kt MF; Bharti SK; Devana SK; Bansal D
Sci Rep; 2024 May; 14(1):11116. PubMed ID: 38750153
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI
PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615
[TBL] [Abstract][Full Text] [Related]
18. WITHDRAWN: Tamsulosin for benign prostatic hyperplasia.
Wilt TJ; Macdonald R; Rutks I
Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD002081. PubMed ID: 21901681
[TBL] [Abstract][Full Text] [Related]
19. Tamsulosin for benign prostatic hyperplasia.
Wilt TJ; Mac Donald R; Rutks I
Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia.
Zhou Z; Cui Y; Wu J; Ding R; Cai T; Gao Z
BMC Urol; 2019 Mar; 19(1):17. PubMed ID: 30871552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]